Wilmington Pharmaceuticals develops and licenses formulations for drug developments.
At Wilmington Pharmaceuticals, they develop and out-license patient-friendly, fast-dissolving formulations for established medicines. They achieve FDA approval and rapid commercialization for their licensing partners, minimizing regulatory risk while maximizing economic opportunity. Their points of differentiation provide you with an ideal development partner.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Oct 26, 2006 | Series B | $1.30M | 2 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Emergent Growth Fund | — | Series B |
Wilmington Investor Network | — | Series B |